Ann McCarthy

Ann McCarthy Elevated to Combined Chief Operating Officer and Chief Financial Officer Position for ZeaVision, Maker of EyePromise Nutraceuticals ST. LOUIS, Missouri (October 9, 2013) – Ann McCarthy has been named Chief Operating Officer of ZeaVision, the St. Louis-based manufacturer of EyePromise nutraceuticals, scientifically shown to support eye heath and enhance visual acuity. In Ms. McCarthy’s new role she will lead the company’s expansion into new markets and new products. Ms. McCarthy became ZeaVision’s Chief Financial Officer in 2010 and will continue her leadership in this role. She brings more than 30 years of experience in finance, accounting, marketing and operations to the company from positions at Peat, Marwick and Mitchell, Kimberly Clark, Ralston Purina, Nestle and Dallas Area Rapid Transit. Ms. McCarthy is a Certified Public Accountant, earned a BS from Iowa State University, MBA from University of Wisconsin-Oshkosh and has completed all but her disquisition for a Doctor of Management from Webster University. She has been recognized with the prestigious Effie award for her work on Energizer EZ Change hearing aid batteries and was selected as a Corporate Woman of the Year by Women in Business. She currently is a Family Advisor for St. Louis Children’s Hospital and serves on their Safety committee. About ZeaVision and EyePromise ZeaVision is passionate about preserving healthy vision and fighting vision loss. The company develops innovative nutraceutical and instrumentation technology for eye care professionals, patients, and consumers. ZeaVision scientists have conducted more than 20 years of research and development in nutrition and eye health and hold patents on zeaxanthin, a crucial dietary antioxidant and photo-protectant. The company also offers a state-of-the-art macular pigment measurement instrument as part of its Eye-Q Intelligent AMD Risk Management Program. TheQuantifEye instrument measures macular pigment optical density and allows eye care professionals to measure, manage, monitor, and maintain healthy macular pigment levels to address an important AMD risk factor. www.eyepromise.com